Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
Page 17 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
Diapositiva 1
Poly-Metastatic Hormone-Sensitive Disease
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial
APCCC 2019: Synthesis - Optimal Treatment of Men with Newly Diagnosed Prostate Cancer
Prostate Cancer News, Reviews & Views: CHAARTED
EAU 2019: Conclusions from Recent Oncology Meetings Regarding: Hormone Naïve Prostate Cancer
Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC
New in management of hormone sensitive prostate cancer | PPT
Presentazione standard di PowerPoint
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/publication/344701128/figure/tbl1/AS:947382543978497@1602885008589/Definition-of-high-and-low-volume-and-risk-in-CHAARTED-54-56-and-LATITIDE-57-based.png "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Patient evaluation. Patients with high tumor burden (CHAARTED... | Download Scientific Diagram
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect
Page 47 - PACE: Advanced Prostate Cancer Consensus
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer - ScienceDirect
September 15, 2014 - What Constitutes High-Volume/Extensive Disease? - The ASCO Post
ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
Patient evaluation. Patients with high tumor burden (CHAARTED... | Download Scientific Diagram
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
Thomas E. Keane | Timing of ADT and Chemotherapy
Presentazione standard di PowerPoint
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
